Table 4.

Plasma and tissue concentrations (mean ± SD) of ME-401 and idelalisib in A20 syngeneic model in BALB/c mice 4 and 24 h after the last dose

Compound	Plasma (ng/mL), mean ± SD (CV%)		Tumor (ng/g), mean ± SD (CV%)		Brain (ng/g), mean ± SD (CV%)
	4 h (n = 6)	24 h (n = 6)	4 h (n = 6)	24 h (n = 6)	4 h (n = 6)	24 h (n = 6)
ME-401 75 mg/kg	7225 ± 531 (7.4)	2328 ± 416 (17.9)	225,333 ± 40,582 (18)	151,500 ± 35,799 (23.6)	2603 ± 466 (17.9)	676 ± 48 (7.1)
ME-401 50 mg/kg	4897 ± 467 (9.5)	420 ± 105 (25.1)	99,850 ± 18,001 (18)	48,100 ± 11,569 (24.1)	NE	NE
Idelalisib 50 mg/kg	23.6 ± 4.81 (20.4)	BLQ	61.8 ± 17.6 (28.5)	BLQ	NE	NE

BLQ below limit of quantitation of idelalisib in plasma of 1 ng/mL or 2 ng/mL after 2 × assay dilution, CV coefficient of variation, NE not evaluated, SD standard deviation